Growth ExpectationsSurvey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch, indicating results are likely to be in-line to slightly lower than Street estimates.
Market UncertaintyShares trade at around 5x NTM EV/Sales with much of the weakness priced in, but without expected upside, uncertainty remains on what could reignite investor interest.
Stock PerformanceVCEL shares are down approximately 42% year-to-date following two softer quarters, indicating performance challenges.